Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

baxter international inc. - BAX

BAX

Close Chg Chg %
32.65 0.42 1.29%

Open Market

33.07

+0.42 (1.29%)

Volume: 1.95M

Last Updated:

Nov 21, 2024, 3:31 PM EDT

Trade Now

Company Overview: baxter international inc. - BAX

BAX Key Data

Open

$32.48

 Day Range

32.33 - 33.11

52 Week Range

31.60 - 44.01

 Market Cap

$16.66B

Shares Outstanding

510.59M

 Public Float

506.52M

Beta

0.60

 Rev. Per Employee

N/A

P/E Ratio

142.30

 EPS

$0.23

Yield

355.50%

 Dividend

$0.17

EX-DIVIDEND DATE

Nov 29, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.91M

  

BAX Performance

1 Week
 
 2.10%
 
1 Month
 
 -9.29%
 
3 Months
 
 -13.08%
 
1 Year
 
 -9.41%
 
5 Years
 
 -60.22%
 

BAX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About baxter international inc. - BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

BAX At a Glance

Baxter International, Inc.
One Baxter Parkway
Deerfield, Illinois 60015-4625
Phone 1-224-948-2000 Revenue 14.81B
Industry Medical Specialties Net Income -226,000,000.00
Sector Health Technology Employees 60,000
Fiscal Year-end 12 / 2024
View SEC Filings

BAX Valuation

P/E Current 142.303
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.321
Price to Book Ratio 2.336
Price to Cash Flow Ratio 11.334
Enterprise Value to EBITDA 10.756
Enterprise Value to Sales 2.079
Total Debt to Enterprise Value 0.466

BAX Efficiency

Revenue/Employee 246,883.333
Income Per Employee -3,766.667
Receivables Turnover 5.40
Total Asset Turnover 0.524

BAX Liquidity

Current Ratio 1.476
Quick Ratio 1.042
Cash Ratio 0.492

BAX Profitability

Gross Margin 37.703
Operating Margin 10.801
Pretax Margin -0.695
Net Margin -1.526
Return on Assets -0.269
Return on Equity -1.068
Return on Total Capital -0.334
Return on Invested Capital -0.366

BAX Capital Structure

Total Debt to Total Equity 170.959
Total Debt to Total Capital 63.094
Total Debt to Total Assets 50.799
Long-Term Debt to Equity 137.682
Long-Term Debt to Total Capital 50.813
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Baxter International Inc. - BAX

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
11.67B 12.78B 15.11B 14.81B
Sales Growth
+2.74% +9.52% +18.22% -1.99%
Cost of Goods Sold (COGS) incl D&A
7.00B 7.56B 9.88B 9.23B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
823.00M 890.00M 1.40B 1.26B
Depreciation
601.00M 592.00M 650.00M 611.00M
Amortization of Intangibles
222.00M 298.00M 753.00M 652.00M
COGS Growth
+8.06% +8.10% +30.66% -6.63%
Gross Income
4.68B 5.22B 5.23B 5.58B
Gross Income Growth
-4.32% +11.63% +0.19% +6.79%
Gross Profit Margin
+40.06% +40.83% +34.61% +37.70%
2020 2021 2022 2023 5-year trend
SG&A Expense
2.86B 3.14B 3.93B 3.98B
Research & Development
495.00M 529.00M 602.00M 655.00M
Other SG&A
2.36B 2.61B 3.32B 3.33B
SGA Growth
-4.06% +9.83% +25.07% +1.50%
Other Operating Expense
- - - (2.00M)
-
Unusual Expense
258.00M 446.00M 3.21B 1.09B
EBIT after Unusual Expense
1.56B 1.64B (1.90B) 507.00M
Non Operating Income/Expense
(116.00M) (8.00M) (28.00M) (92.00M)
Non-Operating Interest Income
19.00M 14.00M 20.00M 70.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
152.00M 152.00M 421.00M 518.00M
Interest Expense Growth
- +36.94% +176.97% +23.04%
Gross Interest Expense
161.00M 163.00M 432.00M 533.00M
Interest Capitalized
9.00M 11.00M 11.00M 15.00M
Pretax Income
1.29B 1.48B (2.35B) (103.00M)
Pretax Income Growth
+33.20% +14.32% -259.31% +95.62%
Pretax Margin
+11.07% +11.55% -15.57% -0.70%
Income Tax
182.00M 182.00M 68.00M (34.00M)
Income Tax - Current - Domestic
- (1.00M) 7.00M 6.00M
Income Tax - Current - Foreign
270.00M 329.00M 286.00M 459.00M
Income Tax - Deferred - Domestic
(94.00M) (111.00M) (305.00M) (387.00M)
Income Tax - Deferred - Foreign
6.00M (35.00M) 80.00M (112.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.11B 1.29B (2.42B) (69.00M)
Minority Interest Expense
8.00M 11.00M 12.00M 7.00M
Net Income
1.10B 1.28B (2.43B) (76.00M)
Net Income Growth
+10.09% +16.52% -289.49% +96.88%
Net Margin Growth
+9.44% +10.04% -16.10% -0.51%
Extraordinaries & Discontinued Operations
- - - (150.00M)
-
Discontinued Operations
- - - (150.00M)
-
Net Income After Extraordinaries
1.10B 1.28B (2.43B) (226.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
1.10B 1.28B (2.43B) (226.00M)
EPS (Basic)
2.165 2.5578 -4.8274 -0.4466
EPS (Basic) Growth
+10.09% +18.14% -288.73% +90.75%
Basic Shares Outstanding
509.00M 502.00M 504.00M 506.00M
EPS (Diluted)
2.1315 2.5276 -4.8274 -0.4466
EPS (Diluted) Growth
+10.51% +18.58% -290.99% +90.75%
Diluted Shares Outstanding
517.00M 508.00M 504.00M 506.00M
EBITDA
2.64B 2.97B 2.71B 2.86B
EBITDA Growth
-2.08% +12.57% -8.95% +5.76%
EBITDA Margin
+22.62% +23.26% +17.91% +19.33%

Snapshot

Average Recommendation HOLD Average Target Price 37.818
Number of Ratings 16 Current Quarters Estimate 0.558
FY Report Date 12 / 2024 Current Year's Estimate 2.11
Last Quarter’s Earnings 0.49 Median PE on CY Estimate N/A
Year Ago Earnings 2.60 Next Fiscal Year Estimate 2.632
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 6 11 12
Mean Estimate 0.56 0.51 2.11 2.63
High Estimates 0.84 0.60 2.97 3.25
Low Estimate 0.51 0.45 1.82 2.46
Coefficient of Variance 18.22 11.31 23.15 10.46

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 1 1 1
HOLD 11 12 11
UNDERWEIGHT 1 0 0
SELL 0 1 1
MEAN Hold Hold Hold

Insider Actions for Baxter International Inc. - BAX

Date Name Shares Transaction Value
Jun 6, 2024 Christopher A. Toth EVP,Group Pres, Kidney Care 213,282 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $34.08 per share 7,268,650.56
Jun 6, 2024 David S. Rosenbloom EVP and General Counsel 108,580 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $34.08 per share 3,700,406.40
May 10, 2024 Peter M. Wilver Director 13,267 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Patricia B. Morrison Director 21,367 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Amy A. McBride-Wendell Director 23,876 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Stephen Newman Oesterle Director 27,901 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Catherine R. Smith Director 22,545 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Nancy M. Schlichting Director 14,278 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 William A. Ampofo Director 9,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 D. Brent Shafer Director 13,257 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Stephen H. Rusckowski Director 9,068 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 David S. Wilkes Director 16,274 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Alok Sonig EVP,Group President, Pharma 113,454 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Brian C. Stevens SVP, CAO & Controller 67,538 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Joel Todd Grade EVP and CFO 96,623 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Reaz Rasul EVP,Group Pres, Healthcare 109,187 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 James W. Borzi EVP,Chief Supply Chain Officer 67,735 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Heather Knight EVP,Group Pres,Med Products 160,330 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 Jeanne K. Mason EVP, Chief HR Officer 188,481 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2024 José E. Almeida Chairman, CEO, President 244,924 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Baxter International Inc. in the News